We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
SELLAS Life Sciences Group Inc | NASDAQ:SLS | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.32 | 1.28 | 1.36 | 0 | 09:00:00 |
As filed with the Securities and Exchange Commission on December 31, 2015
Registration No. 333-208330
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
Post-Effective Amendment No. 1
to
FORM S-3
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
GALENA BIOPHARMA, INC.
(Exact name of registrant as specified in its charter)
Delaware | 20-8099512 | |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification Number) |
2000 Crow Canyon Place, Suite 380
San Ramon, California 94583
(855) 855-4253
(Address, including zip code, and telephone number, including area code, of registrants principal executive offices)
Mark W. Schwartz, Ph.D.
President and Chief Executive Officer
Galena Biopharma, Inc.
2000 Crow Canyon Place, Suite 380
San Ramon, California 94583
(855) 855-4253
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
Thomas J. Knapp General Counsel Galena Biopharma, Inc. 2000 Crow Canyon Place, Suite 380 San Ramon, California 94583 |
Dale E. Short Darren T. Freedman TroyGould PC 1801 Century Park East, 16th Floor Los Angeles, CA 90067 | |
(855) 855-4253 | (310) 553-4441 |
Approximate date of commencement of proposed sale to the public: From time to time after the effective date of this registration statement.
If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, check the following box. ¨
If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box. x
If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨
If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨
If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ¨
If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer | ¨ | Accelerated filer | x | |||
Non-accelerated filer | ¨ (Do not check if a small reporting company) | Smaller reporting company | ¨ |
The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.
EXPLANATORY NOTE
Galena Biopharma, Inc. (Galena) is filing this Post-Effective Amendment No. 1 (this Amendment) to its Registration Statement on Form S-3 (the Original Filing), which was filed with the Securities and Exchange Commission on December 4, 2015 and declared effective on December 22, 2015, for the sole purpose of adding to Exhibit 23.3 the signature of BDO USA, LLP, which was inadvertently omitted from Exhibit 23.3 filed with the Original Filing.
Except as described above, this Amendment effects no change to the Original Filing. This Amendment does not reflect events that may have occurred subsequent to the Original Filing date of December 4, 2015.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Ramon, State of California, on December 30, 2015
GALENA BIOPHARMA, INC. | ||
By: | /s/ MARK W. SCHWARTZ | |
Mark W. Schwartz, Ph.D. | ||
President and Chief Executive Officer |
Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated:
Signature | Title | Date | ||
/s/ Mark W. Schwartz |
President and Chief Executive Officer and Director | December 30, 2015 | ||
Mark W. Schwartz, Ph.D. | ||||
/s/ Ryan Dunlap |
Vice President and Chief Financial Officer (Principal Financial and Accounting Officer) | December 30, 2015 | ||
Ryan Dunlap | ||||
/s/ Sanford J. Hillsberg* |
Chairman of the Board | December 30, 2015 | ||
Sanford J. Hillsberg | ||||
/s/ William L. Ashton* |
Director | December 30, 2015 | ||
William L. Ashton | ||||
/s/ Richard Chin* |
Director | December 30, 2015 | ||
Richard Chin, M.D. | ||||
/s/ Stephen S. Galliker* |
Director | December 30, 2015 | ||
Stephen S. Galliker | ||||
/s/ Irving Einhorn* |
Director | December 30, 2015 | ||
Irving Einhorn | ||||
/s/ Steven S. Kriegsman* |
Director | December 30, 2015 | ||
Steven S. Kriegsman | ||||
/s/ Rudolph Nisi* |
Director | December 30, 2015 | ||
Rudolph Nisi, M.D. |
By: | /s/ Mark W. Schwartz | |
Mark W. Schwartz, Ph.D. | ||
As Attorney-in-Fact |
EXHIBIT INDEX
Exhibit |
Description | |
23.3 | Consent of BDO USA, LLP. |
Exhibit 23.3
Consent of Independent Registered Public Accounting Firm
Galena Biopharma, Inc.
San Ramon, California
We hereby consent to the incorporation by reference in the Prospectus constituting a part of this Registration Statement of our report dated March 12, 2013, relating to the consolidated financial statements of Galena Biopharma, Inc. appearing in the Companys Annual Report on Form 10-K/A for the year ended December 31, 2014.
We also consent to the reference to us under the caption Experts in the Prospectus.
/s/ BDO USA, LLP
Seattle, Washington
December 4, 2015
1 Year SELLAS Life Sciences Chart |
1 Month SELLAS Life Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions